Abstract
AIM: To determine celiac disease (CD) prevalence and associated manifestations or risk factors in healthy adult Emiratis.
METHODS: It is a cross-sectional prospective study, recruiting 1197 (573 women and 624 men) healthy Emiratis between September 2007 and April 2008 among those who went to Al Ain Hospital to undertake the prenuptial examination. Test for anti-tissue transglutaminase (tTG) IgA antibodies was used for CD diagnosis. Subjects with positive results in the anti tTG antibodies assay were also tested for anti-endomysial (EMA) IgA antibodies. A structured interview was used to collect basic demographic and clinical recall data including: information on name, contact address, age, gender, education status, previous diagnosis of CD, diagnosis of CD in 1st degree relatives and history of “chronic diarrhea, anemia, headache, hepatitis, diabetes, tumor, and thyroid disorder”.
RESULTS: Fourteen blood samples (1.17%; 14/1197) were seropositive for CD. The latent CD seropositive patients were 13 women and 1 man and therefore the seroprevalence of CD was 1:86 (14/1197) for adult Emiratis: 1:44 (13/573) for women and 1:624 for men. Binary logistic regression revealed that history of chronic anemia (crude OR = 7.09; 95%CI: 2.32-21.61; P = 0.003) and being a woman (OR = 14.46; 95%CI: 1.89-110.91; P = 0.001) were associated with CD seropositivity. Whereas, the thyroid disorder showed a positive association with CD seropositivity that approach statistical significance (OR = 11.30; 95%CI: 1.32-96.95; P = 0.09) and therefore was included in the multiple logistic regression analysis, which showed that CD seropositivity is independently associated only with history of chronic anemia (OR = 4.58; 95%CI: 1.45-14.48; P = 0.01) and being a woman person (OR = 10.47; 95%CI: 1.33-82.14; P = 0.026).
CONCLUSION: Compared to men the CD seroprevalence among women was remarkably higher. The CD association with women and chronic anemia is of importance from a public health perspective.
Keywords: Celiac disease, Epidemiology, Serology, Prevalence, Gender, United Arab Emirates
Core tip: Celiac disease (CD) prevalence is unknown in United Arab Emirates. Screening for CD among adult Emiratis was done by using anti TtG antibodies and anti-endomysial antibodies (EMA) confirmed those positive. A structured interview was used to collect demographic data and clinical history. Eleven hundred ninety seven subjects were included in the study; the seroprevalence was 1:86 for all adults; 1:44 for women; 1:624 for men. Chronic anemia and being a woman independently associated significantly with CD seropositivity. To our knowledge, this is the first study on CD prevalence among Emiratis; reporting the highest gender difference in CD seroprevalence worldwide.
INTRODUCTION
Celiac disease (CD) is a chronic inflammatory condition in the small intestine, as a response to eating gluten in genetically susceptible individuals. Many symptoms are associated with CD including chronic diarrhea, anemia, and iron/vitamins deficiencies; but what is called as silent or latent CD is also common. Therefore, CD is considered as one of the less diagnosed diseases and affected persons are mostly unaware of having the disease. Moreover, diagnosis of CD often is required for extra-intestinal manifestations, including psychiatric[1], skin[2], and autoimmune diseases[3]. Those who remain undiagnosed are at risk of many long-term complications including but not limited to infertility, osteoporosis, and lymphoma. The basis of treatment of CD is abiding to a diet free of gluten[4]. Therefore, timely diagnosis is essential not just to enable proper treatment of symptoms but also to avoid possible complications[5].
The early epidemiological studies of CD in Europe were based on clinical presentation followed by intestinal biopsies led to undervaluing the prevalence of the disease. Development of highly sensitive and specific serological tests on which subsequent epidemiological studies were based upon, resulted in reporting higher CD prevalence and revealing many clinical features of the disease[6]. Although intestinal biopsy is considered as the gold standard in diagnosis, serological tests are needed to screen for people who need the biopsy. Serology is also useful in distinguishing between the disease and the other causes of intestinal villi atrophy. The recommended test for CD screening is anti-tissue transglutaminase (tTG) antibodies. The test detects both IgA and IgG antibodies. The sensitivity of anti tTG antibodies test is more than 90% but the specificity is less compared with anti-endomysial antibody (EMA) test[7]. The tTG test is based on ELISA which is from a cost and time perspective superior to EMA test[8].
CD affects all ages and races worldwide and its prevalence varies from 0.5%-3%. Initially the disease was thought to be largely confined to northern Europe and Australasia and not common in North America and the Middle East, but CD is now known to be prevalent in all those regions[9]. The published prevalence for CD varies between 1:150-1:300 in UK and 1:80-1:122 in Ireland[4], while it was 1:200 among Italian school children which is much more than earlier prevalence based on clinical findings[10]. Hotmeier and Caspary reported that; for each diagnosed CD patient there are approximately 7-10 undiagnosed patients[11]. The above-mentioned findings suggested an analogy to what is called CD iceberg. A study reported a prevalence of 1:96 in north India and the study concluded that CD is more common than expected[12], while the prevalence was 1:50 in Shiraz, Iran[13]. There are few reports from the Middle East and the Gulf on the prevalence of CD, and to our knowledge no study exists on the prevalence of CD in UAE nationals. Therefore, this study aims at estimating the prevalence of CD among healthy adult Emiratis.
MATERIALS AND METHODS
Study design
This study was a prospective cross sectional concerning CD prevalence in Al Ain city among adult Emiratis who were undergoing the tests of prenuptial examination. Sample size calculation was based on an estimated CD prevalence of 1%, and a lower 95% confidence limit of 0.58%. The estimated minimum number of subjects to be included was 1150; and was adjusted to around 1200 to include about 4% more than the required number.
Study area
Al Ain is the second largest city in the Emirate of Abu Dhabi, it is located inland on the country’s eastern border with Oman about 165 km from Abu Dhabi and about 140 km from Dubai. The area of this city covers over 1.17 million hectares mostly of sand dunes, the temperature during the year ranges between 10 °C up to 48 °C. Al Ain city is the country hub for learning, harboring the UAE University and is famous as a tourist destination. The city is divided into 35 districts with a total population of 0.63 million, 30.8% of whom were Emiratis (estimation of mid 2012).
Al Ain Hospital is one of two major governmental hospitals in Al Ain city and at the time of sampling, it was the only place in the city performing the prenuptial examination tests for UAE nationals.
Study population and blood sampling
The study population is Emiratis who visited Al Ain Hospital for the prenuptial examination between September 2007 and April 2008. The inclusion criteria were: being an adult (16 years of age or more), not previously diagnosed as a CD patient and willing to participate in the study. The exclusion criteria were: Emiratis less than 16 years of age, Emiratis who were diagnosed as having CD, Emiratis with serological equivocal results for CD diagnosis and all non-Emiratis. Blood sampling was carried out at Al Ain Hospital; 5 mL was obtained from each subject. Sera were separated on the same day and stored at -80 °C. Sera were tested for anti-tissue transglutaminase (tTG) IgA antibodies, total IgA measurement was carried out for sera which were negative in tTG IgA. Seropositive sera in anti tTG IgA antibodies were tested for anti EMA IgA antibodies and the following criteria were used to define a serum as CD positive: positive in both anti tTG IgA and anti EMA IgA antibody tests; or in sera with total IgA deficiency, positive in both anti tTG IgG and anti EMA IgG antibodies. The criteria for a serum sample to be designated as CD seronegative were if sufficient in total IgA to be negative in anti tTG IgA, or if deficient in total IgA to be negative in anti tTG IgG.
Demographic and clinical recall data
For each subject a structured interview was done and included information on name, contact address, age, gender, education status, knowledge about CD, if he/she was previously diagnosed as CD patient, diagnosis of CD in 1st degree relatives, history of: chronic diarrhea, anemia, headache, diabetes, tumor, hepatitis and thyroid disorder.
Anti tTG IgA antibodies
Anti tTG IgA antibodies were measured using an ELISA method based on human recombinant transglutaminase (IBL International, Hamburg, Germany). The test was carried out according to the manufacturer instruction. Interpreting the results for tTG IgA qualitatively was based on OD cutoff ratio values as described in the footnote of Table 1.
Table 1.
Subject | Gender | Age | tTG IgA1 | EMA IgA | Clinical history |
1 | M | 24 | 7.6 | +++ | a |
2 | F | 28 | 1.27 | + | t |
3 | F | 22 | 2.42 | +++ | n |
4 | F | 24 | 3.6 | ++ | n |
5 | F | 23 | 8.25 | +++ | a |
6 | F | 20 | 3.15 | ++ | n |
7 | F | 20 | 6.6 | +++ | n |
8 | F | 22 | 4.87 | +++ | a |
9 | F | 25 | 9.1 | +++ | n |
10 | F | 18 | 9.89 | + | a |
11 | F | 24 | 9.13 | +++ | n |
12 | F | 27 | 7.6 | + | n |
13 | F | 24 | 4.25 | +++ | n |
14 | F | 22 | 6.78 | ++ | a |
Using qualitative evaluation ratio for tissue transglutaminase (tTG) IgA the cutoff for the positive > 1.2, equivocal 0.85-1.2, and negative subjects < 0.85. a: Anemia; t: Thyroid disorder; n: No complain; M: Male; F: Female; EMA: Anti-endomysial antibodies.
Total human serum IgA
Quantitative determination of human IgA in serum was carried out using an ELISA method. The test was carried out according to the manufacturer recommendation (XEMA, Medica Co., Moscow, Russia). Sera with IgA level < 0.05 g/L are considered IgA deficient.
Anti-endomysial IgA antibody
The test is based on indirect immunofluorescence assay for semi-quantitative assessment of endomysial antibodies. The test was carried out according to the manufacturer instruction (Immco diagnostics, New York, United States).
Ethical aspects
Al Ain Medical District Human Research Ethics Committee approved the ethical application in July 2007. Upon fully explaining the objectives and the expected benefits from participating in the study, each subject included in the study gave his/her consent for the blood sample and to provide the required information for the structured interview.
Statistical analysis
Data analysis was carried out on personal computer using SPSS (version 15, SPSS Inc., Chicago, IL, United States). The difference in age between “men and women” and between “diabetics and non-diabetics” was assessed by the student’s t-test. The linear by linear (for ordinal variables), the Pearson χ2 test and the Fisher exact test were used to compare dichotomous nominal variables between women and men. Binary and multiple logistic regressions were used to analyze the association between the variables obtained from the structured interview with CD serology.
RESULTS
Study population attributes
Fourteen hundred and thirty persons were requested to participate in the study and 1211 (84.7%) approved. Fourteen were excluded due to grossly hemolyzed samples (11) or equivocal CD serology (3). Therefore, 1197 Emiratis (573 women and 624 men) were included in the study. The age range was 16-70 years with a mean ± SD of 24.87 ± 6.35. The mean age for men 26.36 ± 7.413 was higher (P < 0.001) compared to women 23.247 ± 4.427. The distribution according to age of the study population into 6 groups (16-20, 21-25, 26-30, 31-35, 36-40 and > 40 years of age) and according to gender, showed that most men and women (87.4%) were between 16 and 30 years and there were more men in all the age groups except in the age group 16-20 years (data not shown).
Serological data
All sera tested for total IgA antibodies were IgA sufficient (data not shown). Fourteen blood samples (1.17%; 14/1197) were seropositive for anti tTG IgA and anti EMA IgA and fulfilled the CD seropositive definition and therefore their donors were considered serologically as CD patients (Table 1). The 14 seropositive patients were 13 women and 1 man and therefore the seroprevalence of CD was 1:86 (14/1197) for adult Emiratis: 1:44 (13/573) for women and 1: 624 for men.
Association of variables with CD serology
In order to test for any association between variables obtained through the structured interview and CD serology, results of binary logistic regression analyses are presented in Table 2. The History of chronic anemia (OR = 7.09, 95%CI: 2.32-21.61, P = 0.003) and being a woman (OR = 14.46; 95%CI: 1.89-110.91, P < 0.001) were associated with CD seropositivity. Whereas, the thyroid disorder showed a positive association with CD serology that approach statistical significance (OR = 11.30; 95%CI: 1.32-96.95, P = 0.09) and therefore was included in the multiple logistic regression analysis. Using multiple logistic regressions (for the statistically significant variables in binary logistic regression in addition to the variable thyroid disorder) revealed that only history of chronic anemia and being a woman were independently associated with CD serology (Table 2). Five out of the 14 CD patients reported a history of chronic anemia and one patient reported a thyroid disorder. None of the remaining eight CD patients complained from diarrhea or any symptoms or signs of any disease (Table 1).
Table 2.
Variable | CD-ve | CD+ve | 1OR (95%CI) [P value] | 2OR (95%CI) [P value] | |
CD in family | No3 | 1181 (99.8) | 14 (100) | 0.998 (0.99-1.00) | - |
Yes | 2 (0.2) | 0 (0.0) | [0.828] | ||
Anemia | No3 | 1097 (92.7) | 9 (64.3) | 7.09 (2.32-21.61) | 4.58 (1.45-14.48) |
Yes | 86 (7.3) | 5 (35.7) | [0.003] | [0.01] | |
Headache | No3 | 1171 (99.0) | 14 (100) | 0.997 (0.99-1.00) | - |
Yes | 12 (1.0) | 0 (0.0) | [0.594] | ||
Diarrhea | No3 | 1178 (99.6) | 14 (100) | 0.99 (0.98-1.00) | - |
Yes | 5 (0.4) | 0 (0.0) | [0.731] | ||
Diabetes | No3 | 1162 (98.2) | 14 (100) | 0.996 (0.99-1.00) | - |
Yes | 21 (1.7) | 0 (0.0) | [0.480] | ||
Tumor | No3 | 1182 (99.9) | 14 (100) | 0.98 (0.97-0.99) | - |
Yes | 1 (0.1) | 0 (0.0) | [0.878] | ||
Thyroid disorder | No3 | 1175 (99.3) | 13 (92.9) | 11.30 (1.32-96.95) | - |
Yes | 8 (0.7) | 1 (7.1) | [0.09] | ||
Hepatitis | No3 | 1172 (99.1) | 14 (100) | 0.998 (0.99-1.00) | - |
Yes | 11 (0.9) | 0 (0.0) | [0.610] | ||
Sex | Man3 | 623 (52.7) | 1 (7.1) | 14.46 (1.89-110.91) | 10.47 (1.33-82.14) |
Woman | 560 (47.3) | 13 (92.9) | [0.001] | [0.026] |
1Crude odd ratio; 2Adjusted odd ratio;
Reference group. CD: Celiac disease.
CD serology and structural interview variables in men and women
The distribution of gender in relation to CD serology and the structural interview data was analyzed. Most of the CD seropositive were women (P = 0.0006) and most of the anemic persons were women (P < 0.001), whereas, most of the diabetics were men (P < 0.005). The difference in diabetes between the two sexes is most likely due to age. Diabetics (mostly men) had significantly higher (P < 0.001) age (35.76 ± 12.454) than non-diabetics (24.67 ± 6.028). No other significant difference in the studied variables was found between the two sexes (Table 3).
Table 3.
Parameter | Frequency | Men | Women | P value | |
CD Serology | -ve | 1183 (98.8) | 623 (99.8) | 560 (97.7) | 0.00061 |
+ve | 14 (1.2) | 1 (0.2) | 13 (2.3) | ||
CD in family | No | 1195 (99.8) | 624 (100) | 571 (99.7) | 0.2291 |
Yes | 2 (0.2) | 0 (0.0) | 2 (0.3) | ||
Anemia | No | 1106 (92.4) | 601 (96.3) | 505 (88.1) | < 0.0012 |
Yes | 91 (7.6) | 23 (3.7) | 68 (11.9) | ||
Headache | No | 1185 (99.0) | 618 (99.0) | 567 (99.0) | 1.0002 |
Yes | 12 (1.0) | 6 (1.0) | 6 (1.0) | ||
Diarrhea | No | 1192 (99.6) | 621 (99.5) | 571 (99.7) | 1.01 |
Yes | 5 (4.4) | 3 (0.5) | 2 (0.3) | ||
Diabetes | No | 1176 (98.2) | 606 (97.1) | 570 (99.5) | < 0.0052 |
Yes | 21 (1.8) | 18 (2.9) | 3 (0.5) | ||
Tumor | No | 1196 (99.9) | 623 (99.8) | 573 (100) | 1.01 |
Yes | 1 (0.1) | 1 (0.2) | 0 (0.0) | ||
Thyroid disorder | No | 1188 (99.2) | 622 (99.7) | 566 (98.8) | 0.0961 |
Yes | 9 (0.8) | 2 (0.3) | 7 (1.2) | ||
Hepatitis | No | 1186 (99.1) | 617 (98.9) | 569 (99.3) | 0.6422 |
Yes | 11 (0.9) | 7 (1.1) | 4 (0.7) |
Fisher's Exact Test;
χ2 with continuity correction. CD: Celiac disease.
DISCUSSION
The epidemiological pattern of CD in the world has changed due to many factors e.g., more awareness to the wide variation in the clinical presentations of CD and discovering new serological tests which are simpler, inexpensive and led to increase in the power of detection and hence increase in the reported prevalence of CD[6]. The new serological tests have helped in diagnosis of CD and reporting a higher disease prevalence (1:133) in some countries[14]. However, the actual prevalence of CD is still not clear in spite of these efforts to detect the disease.
In the Middle East, there are few studies on the prevalence of CD in the general population, most of the studies focus on populations at risk, such as those having autoimmune disease e.g., diabetes mellitus type I and autoimmune thyroiditis[15]. Generally CD prevalence is undervalued and its clinical features have not been fully determined due to small sample size, selection bias, limited knowledge about CD and insufficient research funds[6,16]. In Libya, as an example of a Middle East country, CD prevalence among school students was (1:41) much higher than those reported in Europe or North America[17]. In Saudi Arabia, CD prevalence among healthy adolescents was (1:45) for both sexes; (1:33) for females and (1:68) for males. The investigators concluded that the CD prevalence in their study may be among the highest worldwide[18].
To our knowledge, this is the first study on CD prevalence in UAE. This study is prospective cross-sectional concerning CD prevalence among adult UAE nationals who were in the course of undertaking the prenuptial examination. The prenuptial tests include screening for HIV, hepatitis B, syphilis and anemia. The only targeted population was men and women who were apparently healthy at time of recruitment. Choosing this population is satisfactory because the aim of the study is to detect silent/latent CD in healthy adult UAE nationals. Furthermore, from a logistic point of view, those Emiratis were in the process of giving blood for the prenuptial tests, therefore, there was no need for much effort to persuade them to participate in the study. Moreover, the choice of the study population may be reason for the nearly equal gender ratio in this study. The slight men majority in our study can be explained in part that women refused more to participate in the study compared to men; also, some men came alone because their intention was to marry foreigners and the prenuptial tests for foreigners is not carried at the test center at Al Ain Hospital.
In this study, the overall prevalence of CD is 1:86 among UAE nationals of Al Ain city is higher than the CD prevalence in the general population of Western Europe; in Denmark (1:330), Finland (1:130), Germany (1:500), Italy (1:184) and Netherland (1:198)[8]. The CD high prevalence among healthy adult Emiratis emphasize the CD iceberg terminology (that refers to many undiagnosed CD patients in the general population).
Chronic anemia is a major manifestation of CD; it was shown to be associated with seropositivity for CD. Five seropositive subjects have a history of chronic anemia. Several studies reported anemia as the most common sign of CD among adults. In a study of 200 CD patients, 5% of them were anemic due to nutritional deficiency[19]. Thus, it is suggested that all patients who have anemia or iron deficiency should be examined for CD. Iron deficiency usually affects 2%-5% of adolescents, adult girls and women[20]. Most of the anemic subjects in this study were women, which is in agreement with the fact that anemia is more common in women compared with men.
The women-to-men ratio of those who are seropositive for CD in this study (13:1) is much higher than that reported in Finland (11:21)[21], Sweden (7:3)[22], and Argentina (2:1)[23] but comparable to the ratio reported from eastern Switzerland (10:1)[24]. In this study, the seroprevalence of CD in Emirati women was considerably higher compared with men; this dichotomy in gender-related CD prevalence was more remarkable compared to studies from other countries. Most of our subjects (87.4%) were in the young age category (16-30) which agrees with the conclusion of Dixit and coworkers[25] that “gender disparity was most marked in young adults between the ages 18 and 29 years of whom only 18% of the patients diagnosed with CD were males”. There are unknown factors that contribute to the high prevalence of latent CD among women; two obvious factors are the amount of gluten consumption and the extent of intestinal damage[26]. There is no study comparing the consumption of wheat in women and men in UAE and this study didn’t include this variable in the structured interview. There are indications that autoimmune diseases have common genetic risk factors and many of these are gender-predisposed[27]. Possibly women are genetically more susceptible to environmental exposure factors that affect the immunological processes leading to CD. Smoking may be protective against CD and in UAE men constitute the bulk of smokers[28,29], also some endoscopy-confirmed CD patients who were smokers had negative CD serology[30]. Therefore, smoking may partly explain why in this study the prevalence of celiac disease in men was much lower compared with women. In support of this interpretation a retrospective study, from Sheikh Khalifa Medical City, Abu Dhabi, UAE, reported that only 48% of CD children patients were females[31]. Therefore, on the assumption that those children were nonsmokers at the time of study, it is imperative to interpret the difference in CD prevalence between women and men in this study on epigenetic or environmental factors e.g., smoking rather than on inherent genetic susceptibility between the genders. On the other hand, the gender discrepancy may be related to the failure of the serological test to detect the disease in young men due to hormonal or environmental factors. Therefore, one may suggest that for young men with clinical symptoms suggestive of the disease, endoscopy and biopsy should be the basis for diagnosis with less emphasis on the serological tests.
There are some limitations in this study; most of the study population were at the age range of 16-30 years; therefore, compared to the general population older age groups were less represented. The diagnosis relied only on highly specific serological tests but was not proved by biopsy. There was no information on the diet of the sampled population, but it is well known that due to the modern lifestyle, the consumption of fast food (wheat-based diets) among Emiratis has increased considerably during the last decades[32]. Finally, the study includes only the major risk factors for CD and does not include factors that may be protective against CD such as smoking.
In conclusion, as anemia is a major manifestation rather than a risk factor of CD, gender is the most important risk factor associated with CD seropositivity in this study, with much higher prevalence in women (1:44) compared with men (1:624). These findings are of importance from a public health perspective and should be conveyed to the health authority for raising the awareness of the disease among health workers and the general population. Health workers should know that there are many undiagnosed CD women patients among UAE nationals. Therefore, they should refer any patient with vague symptoms, complications or signs suggestive of CD to the healthcare specialists for further examination. Among the measures to diagnose latent/silent or unrecognized CD in the general population is the screening of all women who suffer from chronic anemia.
ACKNOWLEDGMENTS
Most of this study is from the M. Sc. thesis of WSJ. We express our sincere appreciation to the Research Affairs at the United Arab Emirates University, for the financial support. We express our gratitude to the staff at Al Ain Hospital; sampling was not possible without their help. Thank to Prof. Miodrag Lukic at College of Medicine and Health Sciences (CMHS), UAE for permission to carry out some of the laboratory analyses at CMHS. Finally, our sincere thanks extend to all subjects who participated in this study.
COMMENTS
Background
Celiac disease (CD) can be easily mistaken for many other diseases due to its vast clinical symptoms and presentations. CD is a chronic inflammatory condition in the small intestine, in response to eating gluten in genetically susceptible individuals. It is a lifelong disease and the only treatment up-to-date is the complete abiding to a gluten-free diet. The highest prevalence of the disease worldwide has been reported in the Middle East. The aim of this study is to determine CD prevalence and associated manifestations or risk factors in healthy adult Emiratis.
Research frontiers
The lack of information on the prevalence of the disease from many countries is hindering the effort to draw a worldwide prevalence map of the disease. There is no previous report on the prevalence of CD in the United Arab Emirates.
Innovations and breakthroughs
The authors have reported for the first time the prevalence of CD among Emiratis. Furthermore, from public health perspective our findings of the highest worldwide gender disparity in the CD prevalence has great impact, the prevalence in women was 1:44 compared with 1:624 in men. The study points to the importance of considering CD as an etiological agent particularly in Emiratis women who suffer from chronic anemia.
Applications
The results suggest that CD is common among young Emiratis women in Al Ain; therefore, further studies on CD in UAE are warranted to determine the actual CD prevalence in UAE.
Peer review
CD prevalence is unknown in UAE and Screening for CD is very important. This is the first study on CD prevalence among Emiratis and it reports the highest gender difference in CD seroprevalence worldwide.
Footnotes
Supported by Research Affairs at the United Arab Emirates University, grant No. 03-04-2-11/08
P- Reviewer: Abenavoli L S- Editor: Ding Y L- Editor: A E- Editor: Liu XM
References
- 1.Addolorato G, Leggio L, D’Angelo C, Mirijello A, Ferrulli A, Cardone S, Vonghia L, Abenavoli L, Leso V, Nesci A, et al. Affective and psychiatric disorders in celiac disease. Dig Dis. 2008;26:140–148. doi: 10.1159/000116772. [DOI] [PubMed] [Google Scholar]
- 2.Abenavoli L, Proietti I, Leggio L, Ferrulli A, Vonghia L, Capizzi R, Rotoli M, Amerio PL, Gasbarrini G, Addolorato G. Cutaneous manifestations in celiac disease. World J Gastroenterol. 2006;12:843–852. doi: 10.3748/wjg.v12.i6.843. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Lauret E, Rodrigo L. Celiac disease and autoimmune-associated conditions. Biomed Res Int. 2013;2013:127589. doi: 10.1155/2013/127589. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Ciclitira PJ, Moodie SJ. Transition of care between paediatric and adult gastroenterology. Coeliac disease. Best Pract Res Clin Gastroenterol. 2003;17:181–195. doi: 10.1016/s1521-6918(02)00147-6. [DOI] [PubMed] [Google Scholar]
- 5.Fasano A. Should we screen for coeliac disease? Yes. BMJ. 2009;339:b3592. doi: 10.1136/bmj.b3592. [DOI] [PubMed] [Google Scholar]
- 6.Accomando S, Cataldo F. The global village of celiac disease. Dig Liver Dis. 2004;36:492–498. doi: 10.1016/j.dld.2004.01.026. [DOI] [PubMed] [Google Scholar]
- 7.Green PH, Rostami K, Marsh MN. Diagnosis of coeliac disease. Best Pract Res Clin Gastroenterol. 2005;19:389–400. doi: 10.1016/j.bpg.2005.02.006. [DOI] [PubMed] [Google Scholar]
- 8.Guandalini S, Gupta P. Do you still need a biopsy to diagnose celiac disease? Curr Gastroenterol Rep. 2001;3:385–391. doi: 10.1007/s11894-001-0080-x. [DOI] [PubMed] [Google Scholar]
- 9.Kang JY, Kang AH, Green A, Gwee KA, Ho KY. Systematic review: worldwide variation in the frequency of coeliac disease and changes over time. Aliment Pharmacol Ther. 2013;38:226–245. doi: 10.1111/apt.12373. [DOI] [PubMed] [Google Scholar]
- 10.Mulder CJ, Cellier C. Coeliac disease: changing views. Best Pract Res Clin Gastroenterol. 2005;19:313–321. doi: 10.1016/j.bpg.2005.01.006. [DOI] [PubMed] [Google Scholar]
- 11.Holtmeier W, Caspary WF. Celiac disease. Orphanet J Rare Dis. 2006;1:3. doi: 10.1186/1750-1172-1-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Makharia GK, Verma AK, Amarchand R, Bhatnagar S, Das P, Goswami A, Bhatia V, Ahuja V, Datta Gupta S, Anand K. Prevalence of celiac disease in the northern part of India: a community based study. J Gastroenterol Hepatol. 2011;26:894–900. doi: 10.1111/j.1440-1746.2010.06606.x. [DOI] [PubMed] [Google Scholar]
- 13.Dehghani SM, Haghighat M, Mobayen A, Rezaianzadeh A, Geramizadeh B. Prevalence of celiac disease in healthy Iranian school children. Ann Saudi Med. 2013;33:159–161. doi: 10.5144/0256-4947.2013.159. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Niewinski MM. Advances in celiac disease and gluten-free diet. J Am Diet Assoc. 2008;108:661–672. doi: 10.1016/j.jada.2008.01.011. [DOI] [PubMed] [Google Scholar]
- 15.Rostami K, Malekzadeh R, Shahbazkhani B, Akbari MR, Catassi C. Coeliac disease in Middle Eastern countries: a challenge for the evolutionary history of this complex disorder? Dig Liver Dis. 2004;36:694–697. doi: 10.1016/j.dld.2004.05.010. [DOI] [PubMed] [Google Scholar]
- 16.Barada K, Bitar A, Mokadem MA, Hashash JG, Green P. Celiac disease in Middle Eastern and North African countries: a new burden? World J Gastroenterol. 2010;16:1449–1457. doi: 10.3748/wjg.v16.i12.1449. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Alarida K, Nobile S, Catassi C. Coeliac disease in Libya. Dig Liver Dis. 2006;38:A108–A109. [Google Scholar]
- 18.Aljebreen AM, Almadi MA, Alhammad A, Al Faleh FZ. Seroprevalence of celiac disease among healthy adolescents in Saudi Arabia. World J Gastroenterol. 2013;19:2374–2378. doi: 10.3748/wjg.v19.i15.2374. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Howard MR, Turnbull AJ, Morley P, Hollier P, Webb R, Clarke A. A prospective study of the prevalence of undiagnosed coeliac disease in laboratory defined iron and folate deficiency. J Clin Pathol. 2002;55:754–757. doi: 10.1136/jcp.55.10.754. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Ballinger A. Gastroenterology and anemia. Medicine. 2007;35:142–146. [Google Scholar]
- 21.Verkasalo MA, Raitakari OT, Viikari J, Marniemi J, Savilahti E. Undiagnosed silent coeliac disease: a risk for underachievement? Scand J Gastroenterol. 2005;40:1407–1412. doi: 10.1080/00365520510023792. [DOI] [PubMed] [Google Scholar]
- 22.Ivarsson A, Persson LA, Juto P, Peltonen M, Suhr O, Hernell O. High prevalence of undiagnosed coeliac disease in adults: a Swedish population-based study. J Intern Med. 1999;245:63–68. doi: 10.1046/j.1365-2796.1999.00403.x. [DOI] [PubMed] [Google Scholar]
- 23.Gomez JC, Selvaggio GS, Viola M, Pizarro B, la Motta G, de Barrio S, Castelletto R, Echeverría R, Sugai E, Vazquez H, et al. Prevalence of celiac disease in Argentina: screening of an adult population in the La Plata area. Am J Gastroenterol. 2001;96:2700–2704. doi: 10.1111/j.1572-0241.2001.04124.x. [DOI] [PubMed] [Google Scholar]
- 24.Rutz R, Ritzler E, Fierz W, Herzog D. Prevalence of asymptomatic celiac disease in adolescents of eastern Switzerland. Swiss Med Wkly. 2002;132:43–47. doi: 10.4414/smw.2002.09793. [DOI] [PubMed] [Google Scholar]
- 25.Dixit R, Lebwohl B, Ludvigsson JF, Lewis SK, Rizkalla-Reilly N, Green PH. Celiac disease is diagnosed less frequently in young adult males. Dig Dis Sci. 2014;59:1509–1512. doi: 10.1007/s10620-014-3025-6. [DOI] [PubMed] [Google Scholar]
- 26.Guandalini S, Kelly CP. Toward optimal health: Stefano Guandalini [corrected] M.D., and Ciaran P. Kelly, M.D. Discuss celiac disease. Interview by Jodi R Godfrey. J Womens Health (Larchmt) 2005;14:110–116. doi: 10.1089/jwh.2005.14.110. [DOI] [PubMed] [Google Scholar]
- 27.Ivarsson A. The Swedish epidemic of coeliac disease explored using an epidemiological approach--some lessons to be learnt. Best Pract Res Clin Gastroenterol. 2005;19:425–440. doi: 10.1016/j.bpg.2005.02.005. [DOI] [PubMed] [Google Scholar]
- 28.Vazquez H, Smecuol E, Flores D, Mazure R, Pedreira S, Niveloni S, Mauriño E, Bai JC. Relation between cigarette smoking and celiac disease: evidence from a case-control study. Am J Gastroenterol. 2001;96:798–802. doi: 10.1111/j.1572-0241.2001.03625.x. [DOI] [PubMed] [Google Scholar]
- 29.Al-Houqani M, Ali R, Hajat C. Tobacco smoking using Midwakh is an emerging health problem--evidence from a large cross-sectional survey in the United Arab Emirates. PLoS One. 2012;7:e39189. doi: 10.1371/journal.pone.0039189. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Prasad S, Thomas P, Nicholas DS, Sharer NM, Snook JA. Adult endomysial antibody-negative coeliac disease and cigarette smoking. Eur J Gastroenterol Hepatol. 2001;13:667–671. doi: 10.1097/00042737-200106000-00009. [DOI] [PubMed] [Google Scholar]
- 31.El Dannan H, Miqdady M. Descriptive study of celiac disease among children in UAE. Proceedings of the 5th Annual Abu Dhabi Health Services Co. (SEHA) Research Conference; 2013 Dec 15-16. Abu Dhabi: United Arab Emirates; 2013. Abstr 126 pp. [Google Scholar]
- 32.Ng SW, Zaghloul S, Ali H, Harrison G, Yeatts K, El Sadig M, Popkin BM. Nutrition transition in the United Arab Emirates. Eur J Clin Nutr. 2011;65:1328–1337. doi: 10.1038/ejcn.2011.135. [DOI] [PMC free article] [PubMed] [Google Scholar]